ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
24.81
+1.38 (5.89%)
At close: Mar 9, 2026, 4:00 PM EDT
24.81
0.00 (0.00%)
After-hours: Mar 9, 2026, 4:10 PM EDT

ArriVent BioPharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22
Net Income
-166.31-80.49-69.33-36.91
Stock-Based Compensation
12.523.210.90.42
Other Adjustments
-3.03---
Changes in Accounts Payable
2.14-0.751.382.8
Changes in Accrued Expenses
6.676.381.563.61
Changes in Other Operating Activities
-12.581.449.66-13.56
Operating Cash Flow
-160.59-70.21-55.84-43.63
Purchases of Investments
-272.93-194.16-25-
Proceeds from Sale of Investments
201.711.725-
Investing Cash Flow
-71.23-192.47--
Issuance of Common Stock
203.13186.580.350.02
Net Common Stock Issued (Repurchased)
203.13186.580.350.02
Issuance of Preferred Stock
--44.92169.71
Net Preferred Stock Issued (Repurchased)
--44.92169.71
Other Financing Activities
-0.07--2.41-
Financing Cash Flow
203.06186.5842.86169.72
Net Cash Flow
-28.75-76.1-12.98126.09
Free Cash Flow
-160.59-70.21-55.84-43.63
Free Cash Flow Per Share
-4.18-2.23-26.08-34.16
Levered Free Cash Flow
-170.08-73.42-56.74-44.06
Unlevered Free Cash Flow
-181.31-87.24-61.99-44.06
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q